Results 141 to 148 of about 11,617 (148)

Comparison of clinical outcomes of intravitreal ranibizumab and aflibercept treatment for retinopathy of prematurity

Graefe's Archive for Clinical and Experimental Ophthalmology, 2018
Yusuf Koçluk, Emine Alyamac Sukgen, Koçluk Yusuf   +2 more
exaly  

A phase II study of aflibercept in patients with advanced epithelial ovarian cancer and symptomatic malignant ascites

Gynecologic Oncology, 2012
Serafina Mammoliti, Giorgia Mangili, Nicoletta Colombo   +2 more
exaly  

Subfoveal Choroidal Thickness during Aflibercept Therapy for Neovascular Age-Related Macular Degeneration

Ophthalmology, 2016
Ichiro Maruko, Tetsuju Sekiryu, Annabelle Okada   +2 more
exaly  

Evaluation of pain during intravitreal aflibercept injections

European Journal of Ophthalmology, 2018
Merve Inanç, Pelin Yilmazbas
exaly  

Intravitreal aflibercept 8 mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase 2/3 trial

Lancet, The
Karen Wendy Chu, Jeffrey Heier
exaly  

A pharmacoepidemiologic study of ranibizumab and aflibercept use 2013–2016. The Fight Retinal Blindness! Project

Graefe's Archive for Clinical and Experimental Ophthalmology, 2018
Vincent Daien, Mark Gillies, Vuong Nguyen   +2 more
exaly  

Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial

Lancet, The
Karen Wendy Chu, , Robert Vitti
exaly  

Outcomes of Treatment-Resistant Neovascular Age-Related Macular Degeneration Switched from Aflibercept to Faricimab

Ophthalmology Retina
Michael Grinton, Raffaele Raimondi, David Steel   +2 more
exaly